Abstract
Background: Although bevacizumab and monoclonal antibodies directed against epidermal growth factor receptor (EGFR) cetuximab and panitumumab are commonly used in the treatment of metastatic colorectal cancer (mCRC) without activating RAS mutations, the optimal sequencing of these agents is currently unclear.